% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Schneider:835112,
      author       = {Schneider, Christian and Wunderlich, Gilbert and Bleistein,
                      Johannes and Fink, Gereon Rudolf and Deckert, Martina and
                      Brunn, Anna and Lehmann, Helmar Christoph},
      title        = {{L}ymphocyte antigens targetable by monoclonal antibodies
                      in non-systemic vasculitic neuropathy},
      journal      = {Journal of neurology, neurosurgery, and psychiatry},
      volume       = {88},
      number       = {9},
      issn         = {1468-330X},
      address      = {London},
      publisher    = {BMJ Publishing Group},
      reportid     = {FZJ-2017-04980},
      pages        = {756–760},
      year         = {2017},
      abstract     = {Objective To identify the most relevant antigens for
                      monoclonal antibodies in lymphocytic infiltrates in
                      non-systemic vasculitic neuropathy (NSVN).Background Current
                      immunosuppressive treatment for NSVN is insufficient.
                      Monoclonal antibodies might be a treatment option, but the
                      expression profile for targetable antigens on lymphocytic
                      infiltrates in NSVN is unknown.Methods Sural nerve biopsies
                      from a cohort of patients with NSVN were
                      immunohistochemically studied for the expression of
                      potential candidate antigens in perivascular and intramural
                      lymphocytic infiltrates and correlated with neurological and
                      electrophysiological parameters. 20 patients with
                      treatment naïve NSVN and 5 patients with idiopathic axonal
                      neuropathy were included.Results The CD52, BAFF and CD49d
                      antigens were expressed in epineurial, perivascular or
                      intramural lymphocytes of all (20/20) patients. CD52 was
                      most prominently expressed in $21.49\%$ of all inflammatory
                      infiltrates. BAFF and CD49d were detected in $11.25\%$ and
                      $10.99\%$ of these lymphocytes, respectively. The CD20, CD25
                      and CD126 antigens were found less frequently and at low
                      levels only (CD20: 10/20 patients, $5.84\%$ of lymphocytes;
                      CD25: 17/20 patients, $5.22\%$ of lymphocytes; CD126: 3/20
                      patients, $0.15\%$ of lymphocytes).Conclusion This is the
                      first study in NSVN that identifies antigens expressed by
                      pathogenic lymphocytes, which are potential targets for
                      future monoclonal antibody treatment. Our data suggest that
                      NSVN is amenable to monoclonal antibodies and, moreover,
                      that targeting CD52 may be particularly promising. Our
                      results strongly warrant future clinical trials in NSVN with
                      monoclonal antibodies.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000407777300010},
      pubmed       = {pmid:28550073},
      doi          = {10.1136/jnnp-2017-315878},
      url          = {https://juser.fz-juelich.de/record/835112},
}